Inhibition of choroidal neovascularization by anti-EphB4 monoclonal antibody

Su,Dongfeng; Li,Xiaoqiu; Gao,Dianwen

doi:10.3892/etm.2013.962

Inhibition of choroidal neovascularization by anti-EphB4 monoclonal antibody

Authors:
- Dongfeng Su
- Xiaoqiu Li
- Dianwen Gao
View Affiliations

Affiliations: Department of Ophthalmology, 463rd Hospital of Chinese People's Liberation Army, Shenyang 110042, P.R. China, Department of Neurology, The General Hospital of Shenyang Military Region, Shenyang 110016, P.R. China, Department of Ophthalmology, Shengjing Hospital of China Medical University, Shenyang 110004, P.R. China
Published online on: February 18, 2013 https://doi.org/10.3892/etm.2013.962
Pages: 1226-1230

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of this study was to determine the effect of the EphB4 monoclonal antibody on experimental choroidal neovascularization (CNV) progression. Experimental CNV was established by argon laser photocoagulation. In the experimental group, the EphB4 monoclonal antibody was injected into the vitreous space in the eye specimens on days 0, 3, 6 and 9 after CNV model establishment. In the control group, an equal amount of balanced salt solution was injected at the same time points. On day 10 after CNV model establishment, fluorescein isothiocyanate-dextran endocardial perfusion and choroidal stretched preparation were conducted, respectively, for the two groups. The CNV area in each light spot and the mean values were determined. Histopathological examination was conducted and the ratio of the maximum thickness of the CNV in each light spot to the surrounding normal choroidal thickness, as well as the mean ratio, were calculated. Choroidal stretched preparation confirmed that the CNV of the experimental group was smaller, whereas the CNV of the control group was wider and larger. Quantitative analysis revealed that CNV in the experimental group was significantly inhibited (t=11.84, P<0.01) and that CNV progression in the experimental group was significantly suppressed (t=7.45, P<0.01). Histopathological examination revealed that CNV in the experimental group was thinner and smaller. Vitreous injection of the EphB4 monoclonal antibody inhibits experimental CNV progression. However, its specific mechanism remains unclear. Endogenous EphrinB2/EphB4 regulates ocular neovascularization and may become a new target in treating CNV diseases.

View Figures

View References

1	Héroult M, Schaffner F and Augustin HG: Eph receptor and ephrin ligand-mediated interactions during angiogenesis and tumor progression. Exp Cell Res. 312:642–650. 2006.PubMed/NCBI
2	Kojima T, Chang JH and Azar DT: Proangiogenic role of ephrinB1/EphB1 in basic fibroblast growth factor-induced corneal angiogenesis. Am J Pathol. 170:764–773. 2007. View Article : Google Scholar : PubMed/NCBI
3	Chen J, Hicks D, Brantley-Sieders D, et al: Inhibition of retinal neovascularization by soluble EphA2 receptor. Exp Eye Res. 82:664–673. 2006. View Article : Google Scholar : PubMed/NCBI
4	Zamora DO, Davies MH, Planck SR, et al: Soluble forms of EphrinB2 and EphB4 reduce retinal neovascularization in a model of proliferative retinopathy. Invest Ophthalmol Vis Sci. 46:2175–2182. 2005. View Article : Google Scholar : PubMed/NCBI
5	He S, Ding Y, Zhou J, et al: Soluble EphB4 regulates choroidal endothelial cell function and inhibits laser-induced choroidal neovascularization. Invest Ophthalmol Vis Sci. 46:4772–4779. 2005. View Article : Google Scholar : PubMed/NCBI
6	Edelman JL and Castro MR: Quantitative image analysis of laser-induced choroidal neovascularization. Exp Eye Res. 71:523–533. 2000. View Article : Google Scholar : PubMed/NCBI
7	Zhang J and Hughes S: Role of the ephrin and Eph receptor tyrosine kinase families in angiogenesis and development of the cardiovascular system. J Pathol. 208:453–461. 2006. View Article : Google Scholar : PubMed/NCBI
8	Davis S, Gale NW, Aldrich TH, et al: Ligands for Eph-related receptor tyrosine kinases that require membrane attachment or clustering for activity. Science. 266:816–819. 1994. View Article : Google Scholar : PubMed/NCBI
9	Hamada K, Oike Y, Ito Y, et al: Distinct roles of ephrin-B2 forward and EphB4 reverse signaling in endothelial cells. Arterioscler Thromb Vasc Biol. 23:190–197. 2003. View Article : Google Scholar : PubMed/NCBI
10	Füller T, Korff T, Kilian A, Dandekar G and Augustin HG: Forward EphB4 signaling in endothelial cells controls cellular repulsion and segregation from ephrinB2 positive cells. J Cell Sci. 116:2461–2470. 2003.PubMed/NCBI
11	Maekawa H, Oike Y, Kanda S, et al: Ephrin-B2 induces migration of endothelial cells through the phosphatidylinositol-3 kinase pathway and promotes angiogenesis in adult vasculature. Arterioscler Thromb Vasc Biol. 23:2008–2014. 2003. View Article : Google Scholar : PubMed/NCBI
12	Oike Y, Ito Y, Hamada K, et al: Regulation of vasculogenesis and angiogenesis by EphB/ephrin-B2 signaling between endothelial cells and surrounding mesenchymal cells. Blood. 100:1326–1333. 2002.PubMed/NCBI
13	Helbling PM, Saulnier DM and Brändli AW: The receptor tyrosine kinase EphB4 and ephrin-B ligands restrict angiogenic growth of embryonic veins in Xenopus laevis. Development. 127:269–278. 2000.PubMed/NCBI
14	Zhang XQ, Takakura N, Oike Y, et al: Stromal cells expressing ephrin-B2 promote the growth and sprouting of ephrin-B2(+) endothelial cells. Blood. 98:1028–1037. 2001.PubMed/NCBI
15	Kim I, Ryu YS, Kwak HJ, et al: EphB ligand, ephrinB2, suppresses the VEGF- and angiopoietin 1-induced Ras/mitogen-activated protein kinase pathway in venous endothelial cells. FASEB. 16:1126–1128. 2002.PubMed/NCBI
16	Steinle JJ, Meininger CJ, Forough R, Wu G, Wu MH and Granger HJ: Eph B4 receptor signaling mediates endothelial cell migration and proliferation via the phosphatidylinositol 3-kinase pathway. J Biol Chem. 277:43830–43835. 2002. View Article : Google Scholar : PubMed/NCBI
17	Steinle JJ, Meininger CJ, Chowdhury U, Wu G and Granger HJ: Role of ephrinB2 in human retinal endothelial cell proliferation and migration. Cell Signal. 15:1011–1017. 2003. View Article : Google Scholar : PubMed/NCBI
18	Gale NW and Yancopoulos GD: Growth factors acting via endothelial cell-specific receptor tyrosine kinases: VEGFs, angiopoietins and ephrins in vascular development. Genes Dev. 13:1055–1066. 1999. View Article : Google Scholar : PubMed/NCBI
19	Flanagan JG and Vanderhaeghen P: The ephrins and Eph receptors in neural development. Annu Rev Neurosci. 21:309–345. 1998. View Article : Google Scholar : PubMed/NCBI
20	Adams RH, Wilkinson GA, Weiss C, et al: Roles of ephrinB ligands and EphB receptors in cardiovascular development: demarcation of arterial/venous domains, vascular morphogenesis and sprouting angiogenesis. Genes Dev. 13:295–306. 1999. View Article : Google Scholar
21	Hamada K, Oike Y, Ito Y, et al: Distinct roles of ephrin-B2 forward and EphB4 reverse signaling in endothelial cells. Arterioscler Thromb Vasc Biol. 23:190–197. 2003. View Article : Google Scholar : PubMed/NCBI
22	Erber R, Eichelsbacher U, Powajbo V, et al: EphB4 controls blood vascular morphogenesis during postnatal angiogenesis. EMBO J. 25:628–641. 2006. View Article : Google Scholar : PubMed/NCBI
23	Martiny-Baron G, Korff T, Schaffner F, et al: Inhibition of tumor growth and angiogenesis by soluble EphB4. Neoplasia. 6:248–257. 2004. View Article : Google Scholar : PubMed/NCBI
24	Xu Z, Jin H and Qian Q: Humanized anti-EphB4 antibodies for the treatment of carcinomas and vasculogenesis-related diseases. Expert Opin Ther Pat. 19:1035–1037. 2009. View Article : Google Scholar : PubMed/NCBI
25	Zamora DO, Babra B, Pan Y, Planck SR and Rosenbaum JT: Human leukocytes express ephrinB2 which activates microvascular endothelial cells. Cell Immunol. 242:99–109. 2006. View Article : Google Scholar : PubMed/NCBI